Livemedia Home

Previous Events


Next Events

facebook_icon twitter_icon youtube_icon instagram rss_icon

 Login / Register to Livemedia



Υπενθύμιση κωδικού

A+ | A-
GR | GLOBAL | UK

18/05/2018 Congresses | Video | 7o Συνέδριο Διακαθετηριακής Θεραπείας Καρδιακών Βαλβιδοπαθειών | F.Faletra | Risk stratification in aortic valve disease?

info_icon

 

Δηλώνω υπεύθυνα ότι είμαι γιατρός ή εξασκώ παραϊατρικό επάγγελμα |

I hereby declare that I am medical professional 

 

Συμφωνώ | Άκυρο

291 VIEWS EXPANDCOLLAPSE

Share

59.087 total
405 live
291 video
20.961 photo
Views:

17:30-18:15 SPECIAL LECTURES Πρόεδροι: P.Nihoyannopoulos,E.Iliodromitis 17:30-17:52 Risk stratification in aortic valve disease? R.Rosenhek 17:52-18:15 Facilitated TAVI (next day discharge) and TAVR expansion in lower risk patients J.Velianou

Webtv: THVgreece WebTV
 
Sort by Date | Views

Παρακολουθήστε ζωντανά και αποθηκευμένα το 7o Συνέδριο Διακαθετηριακής Θεραπείας Καρδιακών Βαλβιδοπαθειών  που διοργανώνει το Διαγνωστικό Θεραπευτήριο Κέντρο Αθηνών Υγεία στις 18-19 Μαίου 2018 στο ξενοδοχείο Hilton στην Αθήνα.  

 

Για περισσότερες πληροφορίες πατήστε εδώ.

Webtv: THVgreece WebTV
7o Συνέδριο Διακαθετηριακής Θεραπείας Καρδιακών... 476
7ο Συνέδριο Διακαθετηριακής Θεραπείας Καρδιακών... 364
7ο Συνέδριο Διακαθετηριακής Θεραπείας Καρδιακών... 270
J.Iakovou | Management of stable and unstable... 325
G.Trantalis | Predilatation and postdilation... 293
A.Manginas | Emergent TAVR in AS patients... 324
A.Chalapas | TAVR in patients with end-stage... 370
K.Spargias | How Do I Manage These Challenging... 336
G.Pattakos | Will the Heart Team Survive... 304
G.Katsimagklis | My best and worst TAVR... 333
G.Karavolias | My best and worst TAVR case... 275
V.Tzifos | My best and worst TAVR case of... 317
G.Sianos | My best and worst TAVR case of... 294
S.Pattakos | 300
G.Zacharopoulos | 339
K.Tsioufis | 413
D.Tousoulis | 396
P.Vardas | 342
K. Spargias | 390
K.Raisakis | Aortic Valve Stenosis: Flow... 407
C.Naka | Aortic Valve Stenosis: When the... 369
L.Lakkas | A real-world case example 359
S.Karagiannis | Aortic Valve Stenosis: When... 314
K.Papadopoulos | A real-world case example... 329
P.Kourkoveli | A real-world case example... 364
Κωνσταντίνος Τσιούφης - Αναπληρωτής Καθηγητής... 426
K.Toutouzas | Patients with severe AS and... 320
I.Mastorakou | The imaging conundrum of... 350
Παναγιώτης Βάρδας - 7o Συνέδριο Διακαθετηριακής... 344
J.Velianou | Imaging guided differential... 392
Στρατής Παττακός - 7o Συνέδριο Διακαθετηριακής... 310
N.Pilatis | TAVR device selection for patients... 358
Γρηγόρης Παττακός - 7o Συνέδριο Διακαθετηριακής... 407
D.Tsikaderis | My best and worst TAVR case... 290
C.Arampatzis | My best and worst TAVR case... 323
V.Ninios | My best and worst Mitraclip case... 702
G.Siasos | My best and worst TAVR case of... 272
A.Ziakas | My best and worst TAVR case of... 260
R.Von Bardeleben | Impact of valvular heart... 328
M.Chrissoheris | PVL assessment and is paravalvular... 289
K.Spargias | Transcatheter “Edge-to-Edge”... 298
K.Toutouzas | Patients with severe AS and... 263
V.Bapat | Transcatheter Mitral valve Repair... 260
F.Faletra | Risk stratification in aortic... 291
D.Dvir | The spectrum of bioprostheticvalve... 239
C.Karvounis | The pathophysiology of functional... 247
M.Chrissoheris | Similarities and differences... 265
G.Makavos | Pacemaker-associated Tricuspid... 324
G.Pattakos | Surgical management of Tricuspid... 297
R.Von Bardeleben | Off-label, palliative... 341
K.Spargias | Tricuspid Technology: ViV,... 445
A.Tzifa | Transcatheter Pulmonary Valve... 378
James Velianou - 7th Conference of Transcatheter... 423
Michael Reardon - 7th Conference of Transcatheter... 322
Stephan Von Bardeleben - 3rd International... 273
105
Vinayak Bapat - 7th Conference of Transcatheter... 381
Στέλιος Κωνσταντινίδης - 7o Συνέδριο Διακαθετηριακής... 950
Γιώργος Ζαχαρόπουλος - 7o Συνέδριο Διακαθετηριακής... 350
Danny Dvir - 7th Conference of Transcatheter... 264
Χρίστος Ευτυχίου - 7o Συνέδριο Διακαθετηριακής... 1.336
M.Hamilos | The compelling saga of strokes... 278
K.Toutouzas | Comparison of the various... 331
M.Vavouranakis | TAVR Device Selection and... 350
D.Angouras | A Surgeon’s viewpoint on SAVR... 395
V.Lozos | TAVR alternative access: Transapical,... 315
M.Kasel | Transcaval TAVR for all who cannot... 309
T.Apostolopoulos | Incidence, predictors,... 417
A.Nikitopoulos | My best and worst TAVR... 425
D.Dvir | Management of bioprosthetic valve... 274
C.Eftychiou | Coronary Obstruction during... 1.060
J.Velianou | Importance of imaging in TAVR:... 316
M.Kasel | TAVR for non-calcific Aortic Insufficiency.... 258
G.Latsios | Prevention and management of... 613
D.Nikas | Optimal TAVR device placement... 330
D.Dvir | Techniques and outcomes of Trans-septal... 279
J.Kisslo | Fake news VS fact: Echo imaging... 233
M.Reardon | Low risk TAVR. What the future... 271
M.Reardon | Surgical and Transcatheter Mitral... 328
V.Bapat | Cardiothoracic surgeons and skills... 255
V.Bapat | TMVR today: Access routes and... 339
A.Colli | Transcatheter Mitral Valve chordal... 484
K.Spargias | My best and worst TMVR case... 501
K.Moldovan | TMVR in MAC: Lessons from the... 362
C.Kotoulas | TAVR 2018: The Landscape of... 262
G.Pavlides | TAVR 2018: Are the Guidelines... 364
P.Dardas | i. Pro 242
D.Angouras | ii. Con 236
E.Skalidis | iii. A real-world case example... 239
K.Spargias | i. Pro 256
A.Manolis | ii. Con 272
M.Drakopoulou | iii. A real-world case example... 237
G.Pattakos | The relationship between TAVR... 256
J.Velianou | The spectrum of bioprosthetic... 272
G.Dangas | The latest in TAVR adjunctive... 280
Κλείσιμο Συνεδρίου 334
18/05 ΑΙΘ. SANTORINI
09:00 - 10:30
TAVR club I: Advanced training lectures and clinical controversies 

Evaluated
Evaluation
09:00 - 09:15
Predilatation and postdilation during TAVR. Risks involved and when it should be considered mandatory

Evaluated
Evaluation

Speaker: G. Trantalis

09:15 - 09:30
Emergent TAVR in AS patients with intractable heart failure or cardiogenic shock: Feasibility, selection process and clinical trials evidence

Evaluated
Evaluation

Speaker: A. Manginas

09:30 - 09:45
TAVR in patients with end-stage CKD or οn renal replacement therapy: Special considerations and prevention of early valve failure

Evaluated
Evaluation

Speaker: A. Chalapas

09:45 - 10:00
How Do I Manage These Challenging Case Scenarios? Horizontal aorta, excessive calcium in the annulus and LVOT, sizing in the Gray Zone, borderline femoral access

Evaluated
Evaluation

Speaker: K. Spargias

10:00 - 10:15
Management of stable and unstable Coronary Disease in AS patients: Timing of PCI with TAVR, when to consider CABG, and completeness of revascularization

Evaluated
Evaluation

Speaker: J. Iakovou

10:15 - 10:30
Will the Heart Team Survive the modern era of minimalist TAVR?

Evaluated
Evaluation

Speaker: G. Pattakos

Chairmen: S. Foussas, N. Ioannou, S. Konstantinidis, E. Pissimisis, A. Trikas

10:30 - 11:30
My best and worst TAVR case of the year. The single most important lesson learned  

Evaluated
Evaluation
10:30 - 10:42

Evaluated
Evaluation

Speaker: G. Katsimagklis

10:42 - 10:54

Evaluated
Evaluation

Speaker: G. Karavolias

10:54 - 11:08

Evaluated
Evaluation

Speaker: V. Tzifos

11:08 - 11:20

Evaluated
Evaluation

Speaker: G. Sianos

11:20 - 11:30

Evaluated
Evaluation

Speaker: G. Bompotis

Chairmen: A. Antoniadis, N. Bouboulis, N. Kafkas, S. Papaioannou

11:30 - 12:00
OPENING CEREMONY 

Evaluated
Evaluation
11:30 - 00:00

Evaluated
Evaluation

Speakers: S. Pattakos, G. Zacharopoulos, K. Tsioufis, D. Tousoulis, P. Vardas

12:00 - 12:30
Break 

12:30 - 14:30
TAVR club II: The basics that determine success or failure 

Evaluated
Evaluation
12:30 - 12:45
Aortic Valve Stenosis: Flow and Gradient stratification and association with TAVR outcomes

Evaluated
Evaluation

Speaker: K. Raisakis

12:45 - 13:00
Aortic Valve Stenosis: When the TTE is (or is not) sufficient to make the diagnosis and guide treatment

Evaluated
Evaluation

Speaker: C. Naka

13:00 - 13:15
A real-world case example

Evaluated
Evaluation

Speaker: L. Lakkas

13:15 - 13:30
Aortic Valve Stenosis: When stress TTE and/or TEE is required to make the diagnosis and guide treatment

Evaluated
Evaluation

Speaker: S. Karagiannis

13:30 - 13:45
A real-world case example

Evaluated
Evaluation

Speaker: K. Papadopoulos

13:45 - 14:00
TAVR MSCT screening. Guidance, device selection, and outcomes prediction

Evaluated
Evaluation

Speaker: C. Mourmouris

14:00 - 14:15
A real-world case example

Evaluated
Evaluation

Speaker: P. Kourkoveli

14:15 - 14:30
The imaging conundrum of Bicuspid Aortic Valve Disease

Evaluated
Evaluation

Speaker: I. Mastorakou

Chairmen: C. Chrysohoou, P. Danias, C. Olympios, S. Patsilinakos

14:30 - 16:00
TAVR club II: Complex cases  

Evaluated
Evaluation
14:30 - 14:42
Imaging guided differential balloon filling of Sapien 3: clinical outcomes

Evaluated
Evaluation

Speaker: J. Velianou

14:42 - 14:55
TAVR device selection for patients with small sinuses of Valsalva

Evaluated
Evaluation

Speaker: N. Pilatis

14:55 - 15:08
Repositioning of self-expanding valves: Use cautiously!

Evaluated
Evaluation

Speaker: A. Tzikas

15:08 - 15:20
My best and worst TAVR case of the year. The single most important lesson learned

Evaluated
Evaluation

Speaker: D. Tsikaderis

15:20 - 15:32
My best and worst TAVR case of the year. The single most important lesson learned

Evaluated
Evaluation

Speaker: C. Arampatzis

15:32 - 15:47
My best and worst TAVR case of the year. The single most important lesson learned

Evaluated
Evaluation

Speaker: G. Siasos

15:47 - 16:00
My best and worst TAVR case of the year. The single most important lesson learned

Evaluated
Evaluation

Speaker: A. Ziakas

Chairmen: G. Bompotis, A. Dimas, D. Iliopoulos, E. Koutoulakis

16:00 - 17:30
JOINT MEETING 1 

Aortic and Mitral club

Evaluated
Evaluation
16:00 - 16:15
Impact of valvular heart disease on the global burden of Heart Failure: Can Transcatheter therapies make a difference?

Evaluated
Evaluation

Speaker: S. Von Bardeleben

16:15 - 16:30
PVL assessment. Is paravalvular regurgitation after TAVR still an important consideration in 2017?

Evaluated
Evaluation

Speaker: M. Chrissoheris

16:30 - 16:45
Transcatheter “Edge-to-Edge” Mitral Valve Repair (MitraClip, PASCAL): Updated patient selection criteria and clinical challenges

Evaluated
Evaluation

Speaker: K. Spargias

16:45 - 17:00
Patients with severe AS and significant MR: frequency, management and the role of Mitraclip

Evaluated
Evaluation

Speaker: K. Toutouzas

17:00 - 17:15
Transcatheter Mitral valve Repair and Replacement: Competition or Synergy

Evaluated
Evaluation

Speaker: V. Bapat

17:15 - 17:30
My best and worst Mitraclip case of the year. The single most important lesson learned

Evaluated
Evaluation

Speaker: V. Ninios

Chairmen: S. Adamopoulos, L. Michalis, P. Nihoyannopoulos, M. Vavuranakis

17:30 - 18:15
SPECIAL LECTURES 

Evaluated
Evaluation
17:30 - 17:52
Risk stratification in aortic valve disease?

Evaluated
Evaluation

Speaker: R. Rosenhek

17:52 - 18:15
The spectrum of bioprosthetic valve leaflet thrombosis from subclinical to clinical: incidence and clinical outcomes

Evaluated
Evaluation

Speaker: D. Dvir

Chairmen: P. Nihoyannopoulos, E. Iliodromitis

18:15 - 20:00
JOINT MEETING 2  

Tricuspid club

Evaluated
Evaluation
18:15 - 18:30
Functional Tricuspid Regurgitation: pathophysiology, natural history, medical management, and timing of intervention

Evaluated
Evaluation

Speaker: C. Karvounis

18:30 - 18:45
Similarities and differences in Tricuspid vs. Mitral Valve anatomy and imaging. Echo evaluation of TR severity and procedural guidance for tricuspid interventions

Evaluated
Evaluation

Speaker: M. Chrissoheris

18:45 - 19:00
Pacemaker-associated Tricuspid Regurgitation: Underestimated and tickling the balance in selected patients

Evaluated
Evaluation

Speaker: G. Makavos

19:00 - 19:15
Surgical management of Tricuspid Regurgitation: Implications for transcatheter therapies

Evaluated
Evaluation

Speaker: G. Pattakos

19:15 - 19:30
Off-label, palliative Mitraclip treatment in functional and degenerative Tricuspid Regurgitation

Evaluated
Evaluation

Speaker: S. Von Bardeleben

19:30 - 19:45
Tricuspid Technology: ViV, Forma Spacer, Trialign, Cardioband, Tricinch Millipede, Pascal

Evaluated
Evaluation

Speaker: K. Spargias

19:45 - 20:00
Transcatheter Pulmonary Valve replacement: An update on the solutions available in 2018

Evaluated
Evaluation

Speaker: A. Tzifa

Chairmen: G. Athanassopoulos, A. Avgeropoulou, I. Goudevenos, M. Khoury, G. Stavridis

19/05 ΑΙΘ. SANTORINI
09:00 - 11:00
TAVR club IV: Advanced training lectures and clinical controversies  

Evaluated
Evaluation
09:00 - 09:15
The compelling saga of strokes after TAVR (and SAVR) and the role of cerebral embolic protection devices

Evaluated
Evaluation

Speaker: M. Hamilos

09:15 - 09:30
Comparison of the various TAVR systems: Should clinical and anatomic factors determine TAVR device selection?

Evaluated
Evaluation

Speaker: K. Toutouzas

09:30 - 09:45
TAVR Device Selection and CT Sizing for Bicuspid Aortic Valves. A tutorial of tips and tricks

Evaluated
Evaluation

Speaker: M. Vavouranakis

09:45 - 10:00
A Surgeon’s viewpoint on SAVR vs. TAVR, bioprosthetic valve durability and the role of the Rapid Deployment surgical valves

Evaluated
Evaluation

Speaker: D. Angouras

10:00 - 10:15
TAVR alternative access: Transapical, transaortic, trans-subclavian, suprasternal, transcarotid. For whom and how

Evaluated
Evaluation

Speaker: V. Lozos

10:15 - 10:30
Transcaval TAVR for all who cannot have TF access?

Evaluated
Evaluation

Speaker: M. Kasel

10:30 - 10:45
Incidence, predictors, and consequences of permanent pacemakers after TAVR

Evaluated
Evaluation

Speaker: T. Apostolopoulos

10:45 - 11:00
My best and worst TAVR case of the year. The single most important lesson learned

Evaluated
Evaluation

Speaker: A. Nikitopoulos

Chairmen: Κ. Aggeli, G. Makos, D. Nikas, V. Voudris

11:00 - 11:30
Break 

11:30 - 13:30
TAVR club III: Advanced training lectures and clinical controversies  

Evaluated
Evaluation
11:30 - 11:45
Coronary Obstruction during TAVR: Risk assessment, prevention and treatment

Evaluated
Evaluation

Speaker: C. Eftychiou

11:45 - 12:00
Importance of imaging in TAVR: what a non imaging Structuralist needs to know to obtain best possible results

Evaluated
Evaluation

Speaker: J. Velianou

12:00 - 12:15
Management of bioprosthetic valve failure: A Valve-in-Valve workshop (stented, stentless and small valves, implant depth, PAR, stent fracture)

Evaluated
Evaluation

Speaker: D. Dvir

12:15 - 12:30
TAVR for non-calcific Aortic Insufficiency. Are we there yet?

Evaluated
Evaluation

Speaker: M. Kasel

12:30 - 12:45
Prevention and management of paravalvular leak

Evaluated
Evaluation

Speaker: G. Latsios

12:45 - 13:00
Optimal TAVR device placement to reduce the frequency of conduction abnormalities and PAR

Evaluated
Evaluation

Speaker: D. Nikas

13:00 - 13:30
Cardiothoracic surgeons and skills for structural intervention

Evaluated
Evaluation

Speaker: V. Bapat

Chairmen: A. Pitsis, V. Pyrgakis, A. Spanos, V. Voudris

13:30 - 14:00
Break 

14:00 - 16:00
Mitral club II: Focus on Valve in Valve and TMVR 

Evaluated
Evaluation
14:00 - 14:15
Surgical and Transcatheter Mitral Valve Replacement vs. Repair: Competition or Synergy

Evaluated
Evaluation

Speaker: M. Reardon

14:15 - 14:30
Techniques and outcomes of Trans-septal Valve-in-Ring, Valve-in-Valve, and Valve-in-MAC

Evaluated
Evaluation

Speaker: D. Dvir

14:30 - 14:45
TAVR in Mitral surgical valves and rings: Imaging for Patient and Prosthesis Selection and how to use the Mitral App

Evaluated
Evaluation

Speaker: C. Mourmouris

14:45 - 15:00
TMVR today: Access routes and sizing for Transcatheter Mitral Valve replacement: Clinical and technical considerations

Evaluated
Evaluation

Speaker: V. Bapat

15:00 - 15:15
LVOT obstruction after TMVR: prediction, prevention, management and the role of the Frequency of the LAMPOON procedure

Evaluated
Evaluation

Speaker: D. Dvir

15:15 - 15:30
TMVR in MAC: Lessons from the registries and 3D printing

Evaluated
Evaluation

Speaker: K. Moldovan

15:30 - 15:45
Transcatheter Mitral Valve chordal implantation (NeoChord): For whom and when

Evaluated
Evaluation

Speaker: A. Colli

15:45 - 16:00
My best and worst TMVR case of the year. The single most important lesson learned

Evaluated
Evaluation

Speaker: K. Spargias

Chairmen: D. Katritsis, F. Mitropoulos, A. Pitsis, K. Toutouzas

16:00 - 16:30
Break 

16:30 - 17:30
SPECIAL LECTURES 

Evaluated
Evaluation
16:30 - 17:00
Fake news VS fact: Echo imaging of the aortic valve

Evaluated
Evaluation

Speaker: J. Kisslo

17:00 - 17:30
Low risk TAVR. What the future holds

Evaluated
Evaluation

Speaker: M. Reardon

Chairmen: P. Nihoyannopoulos, A. Pipilis

17:30 - 19:30
Joint Session of the HCS Working Groups: Interventional Cardiology, Cardiothoracic Surgery and Cardiac Valve Disease  

TAVR: Clinical efficacy and cost-effectiveness behind the explosion

Evaluated
Evaluation
17:30 - 17:54
TAVR 2018: The Landscape of Greek and Worldwide Usage

Evaluated
Evaluation

Speaker: C. Kotoulas

17:54 - 18:18
TAVR 2018: Are the Guidelines keeping pace with evidence generation and clinical practice?

Evaluated
Evaluation

Speaker: G. Pavlides

18:18 - 18:42
TAVR 2018: Clinical efficacy according to baseline patient risk. A critical approach

Evaluated
Evaluation
18:18 - 18:26
i. Pro

Evaluated
Evaluation

Speaker: P. Dardas

18:26 - 18:34
ii. Con

Evaluated
Evaluation

Speaker: D. Angouras

18:34 - 18:42
iii. A real-world case example

Evaluated
Evaluation

Speaker: E. Skalidis

18:45 - 19:10
TAVR 2018: Cost-effective according to baseline patient risk!

Evaluated
Evaluation
18:47 - 19:00
i. Pro

Evaluated
Evaluation

Speaker: K. Spargias

19:03 - 19:05
ii. Con

Evaluated
Evaluation

Speaker: A. Manolis

19:05 - 19:10
iii. A real-world case example

Evaluated
Evaluation

Speaker: M. Drakopoulou

19:10 - 19:30
The relationship between TAVR procedure volumes and clinical outcomes and the rationale and need for a tiered national system of valve centers

Evaluated
Evaluation

Speaker: G. Pattakos

Chairmen: A. Dagre, G. Hahalis, I. Kanakakis, L. Michalis, K. Triantafillou, S. Prapas

19:30 - 20:30
Special Lectures  

Evaluated
Evaluation
19:30 - 20:00
The spectrum of bioprosthetic valve leaflet thrombosis from subclinical to clinical: incidence and clinical outcomes

Evaluated
Evaluation

Speaker: J. Velianou

20:00 - 20:30
The latest in TAVR adjunctive pharmacotherapy: The current standards and the case for routine vs. selective anticoagulant therapy

Evaluated
Evaluation

Speaker: G. Dangas

Chairmen: D. Alexopoulos, P. Vardas